User Image Cart Icon 0 Search Image

Anti Atherogenic

  1. The anti-carcinogenic and ANTI-ATHE ROGENICeffects of lycopene: a review
  2. The metabolism and ANTI-ATHEROGENICproperties of HDL
  3. The anti-inflammatory and potential ANTI-ATHEROGENICeffect of insulin: a new paradigm
  4. Anti-inflammatory and ANTI-ATHEROGENICproperties of adiponectin
  5. ANTI-ATHEROGENICeffects of resveratrol
  6. The forgotten face of regular physical exercise: a ‘natural’ANTI-ATHEROGENICactivity
  7. Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an ANTI-ATHEROGENICmediator?
  8. Interferon-γ and atherosclerosis: pro-or ANTI-ATHEROGENIC?
  9. Thiazolidinediones as anti‐inflammatory and anti‐atherogenic agents
  10. Protein composition determines the ANTI-ATHEROGENICproperties of HDL in transgenic mice
  11. Resveratrol and ANTI-ATHEROGENICeffects
  12. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an ANTI-ATHEROGENIClipid profile
  13. ANTI-ATHEROGENICeffects of seabuckthorn (Hippophaea rhamnoides) seed oil
  14. Dual roles of adiponectin/Acrp30 in vivo as an anti-diabetic and ANTI-ATHEROGENICadipokine
  15. Nuts: ANTI-ATHEROGENICfood?
  16. ANTI-ATHEROGENICmechanisms of high density lipoprotein: effects on myeloid cells
  17. ANTI-ATHEROGENICand anti-angiogenic activities of polyphenols from propolis
  18. Evaluation of antioxidant and ANTI-ATHEROGENICproperties of Glycyrrhiza glabra root using in vitro models
  19. Advanced glycation of apolipoprotein AI impairs its ANTI-ATHEROGENICproperties
  20. Insights into the molecular mechanisms of the ANTI-ATHEROGENICactions of flavonoids in normal and obese mice
  21. ANTI-ATHEROGENICeffect of coenzyme Q10 in apolipoprotein E gene knockout mice
  22. Heme oxygenase–carbon monoxide signalling pathway in atherosclerosis: ANTI-ATHEROGENICactions of bilirubin and carbon monoxide?
  23. Antioxidant and ANTI-ATHEROGENICactivities of olive oil phenolics
  24. Natural compounds as ANTI-ATHEROGENICagents: Clinical evidence for improved cardiovascular outcomes
  25. Antioxidant and ANTI-ATHEROGENICactivities of three Piper species on atherogenic diet fed hamsters
  26. Anti-inflammatory and ANTI-ATHEROGENICeffects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice
  27. Evaluation of the ANTI-ATHEROGENICpotential of chrysin in Wistar rats
  28. The hyperpolarizing impact of glycine on endothelial cells may be ANTI-ATHEROGENIC
  29. Vitamin E analogs: a new class of multiple action agents with anti-neoplastic and ANTI-ATHEROGENICactivity
  30. Possible anti‐atherogenic effect of kolaviron (a Garcinia kola seed extract) in hypercholesterolaemic rats
  31. Eicosapentaenoic acid-enriched high-density lipoproteins exhibit ANTI-ATHEROGENICproperties
  32. Cardioprotective effects of high-density lipoprotein beyond its ANTI-ATHEROGENICaction
  33. ANTI-ATHEROGENICand anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus
  34. ANTI-ATHEROGENICeffects of 17β-estradiol
  35. ANTI-ATHEROGENICeffect of nuts: is the answer NO?
  36. An ANTI-ATHEROGENICeffect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol
  37. Naringenin derivatives as ANTI-ATHEROGENICagents
  38. Apolipoprotein mimetic peptides: Mechanisms of action as ANTI-ATHEROGENICagents
  39. Sphingosine 1-phosphate induced ANTI-ATHEROGENICand atheroprotective M2 macrophage polarization through IL-4
  40. ANTI-ATHEROGENICEffect of Laminar Shear Stress via Nrf2 Activation
  41. Regulation of pro-and ANTI-ATHEROGENICcytokines
  42. Neuronal nitric oxide synthase as a novel ANTI-ATHEROGENICfactor
  43. ANTI-ATHEROGENICeffect of insulin in vivo
  44. Phenolic compounds and the ANTI-ATHEROGENICeffect of bee bread in high-fat diet-induced obese rats
  45. ANTI-ATHEROGENICeffect of citrus flavonoids, naringin and naringenin, associated with hepatic ACAT and aortic VCAM-1 and MCP-1 in high cholesterol-fed rabbits
  46. A study of anti-hyperlipidemia, hypolipedimic and ANTI-ATHEROGENICactivity of fruit of Emblica officinalis (amla) in high fat fed albino rats
  47. ANTI-ATHEROGENICproperties of date vs. pomegranate polyphenols: the benefits of the combination
  48. ANTI-ATHEROGENICeffects of orlistat on obesity-induced vascular oxidative stress rat model
  49. Phytosterol supplementation could improve atherogenic and ANTI-ATHEROGENICapolipoproteins: a systematic review and dose–response meta-analysis of randomized …
  50. Apolipoprotein AI mimetic peptide helix number and helix linker influence potentially ANTI-ATHEROGENICproperties
  51. Placental secretion of apolipoprotein A1 and E: the ANTI-ATHEROGENICimpact of the placenta
  52. An experimental evaluation of the ANTI-ATHEROGENICpotential of the plant, Piper betle, and its active constitutent, eugenol, in rats fed an atherogenic diet
  53. ANTI-ATHEROGENICactivity of ethanolic fraction of Terminalia arjuna bark on hypercholesterolemic rabbits
  54. Atherogenic and ANTI-ATHEROGENICfactors in the human diet
  55. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: ANTI-ATHEROGENICrole for paraoxonase-2
  56. Anti‐atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase‐1
  57. ANTI-ATHEROGENICpotential of jujube, saffron and barberry: anti-diabetic and antioxidant actions
  58. Resveratrol mediates ANTI-ATHEROGENICeffects on cholesterol flux in human macrophages and endothelium via PPARγ and adenosine
  59. Nitric oxide enhances the anti-inflammatory and ANTI-ATHEROGENICactivity of atorvastatin in a mouse model of accelerated atherosclerosis
  60. Anti‐Atherogenic Effect of Stem Cell Nanovesicles Targeting Disturbed Flow Sites
  61. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential ANTI-ATHEROGENICfunction?
  62. Glucose lowering and ANTI-ATHEROGENICeffects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors
  63. Anti-oxidant and ANTI-ATHEROGENICproperties of liposomal glutathione: studies in vitro, and in the atherosclerotic apolipoprotein E-deficient mice
  64. Role of sphingosine 1-phosphate in ANTI-ATHEROGENICactions of high-density lipoprotein
  65. Altered activities of ANTI-ATHEROGENICenzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice
  66. ANTI-ATHEROGENICeffects of the methanol extract of Sorbus cortex in atherogenic-diet rats
  67. Anti‐atherogenic effect of berberine on LXRα‐ABCA1‐dependent cholesterol efflux in macrophages
  68. AMPK activation enhances the ANTI-ATHEROGENICeffects of high density lipoproteins in apoE−/− mice
  69. … (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and ANTI-ATHEROGENICeffects
  70. Taurine supplementation has ANTI-ATHEROGENICand anti-inflammatory effects before and after incremental exercise in heart failure
  71. Structural evidence of ANTI-ATHEROGENICmicroRNAs
  72. Inhibition of cytokine-induced vascular cell adhesion molecule-1 expression; possible mechanism for ANTI-ATHEROGENICeffect of Agastache rugosa
  73. Anti‐atherogenic and anti‐inflammatory properties of glucagon‐like peptide‐1, glucose‐dependent insulinotropic polypepide, and dipeptidyl peptidase‐4 inhibitors in …
  74. A review of the cardiovascular and ANTI-ATHEROGENICeffects of ghrelin
  75. ANTI-ATHEROGENICproperty of ferulic acid in apolipoprotein E-deficient mice fed Western diet: comparison with clofibrate
  76. Aminoguanidine has an ANTI-ATHEROGENICeffect in the cholesterol-fed rabbit
  77. Evaluation of the in vitro ANTI-ATHEROGENICactivities of goat milk and goat dairy products
  78. In silico design of ANTI-ATHEROGENICbiomaterials
  79. ANTI-ATHEROGENICactivity of polyphenol-rich extract from bee pollen
  80. Regulation of ANTI-ATHEROGENICapolipoprotein M gene expression by the orphan nuclear receptor LRH-1
  81. Vitamin E: the evidence for an ANTI-ATHEROGENICrole.
  82. ANTI-ATHEROGENICeffect of hydrogen sulfide by over-expression of cystathionine gamma-lyase (CSE) gene
  83. Overexpression of STARD3 in human monocyte/macrophages induces an ANTI-ATHEROGENIClipid phenotype
  84. In vitro ANTI-ATHEROGENICproperties of traditional Greek cheese lipid fractions
  85. ANTI-ATHEROGENICeffect of 10% supplementation of anchovy (Engraulis encrasicolus) waste protein hydrolysates in ApoE-deficient mice
  86. Hypolipidemic and ANTI-ATHEROGENICeffects of long-term Cholestin (Monascus purpureus-fermented rice, red yeast rice) in cholesterol fed rabbits
  87. ANTI-ATHEROGENICeffects of centipede acidic protein in rats fed an atherogenic diet
  88. In vitro Anti‐atherogenic Properties of N‐Heterocyclic Carbene Aurate (I) Compounds
  89. Phytochemical analysis of ANTI-ATHEROGENICconstituents of Xue-Fu-Zhu-Yu-Tang using HPLC-DAD-ESI-MS
  90. A genome scan for loci influencing ANTI-ATHEROGENICserum bilirubin levels
  91. Hypolipidemic and anti‐atherogenic activities of crude polysaccharides from abalone viscera
  92. Enzymatic synthesis of phytosteryl docosahexaneates and evaluation of their ANTI-ATHEROGENICeffects in apo-E deficient mice
  93. Anti-thrombotic and ANTI-ATHEROGENICaction of eicosapentaenoic acid
  94. PPAR Activity in the Vessel Wall: ANTI-ATHEROGENICProperties
  95. … intima-media thickness by reducing small dense low-density lipoproteins in a real-world setting of patients with type 2 diabetes: A novel ANTI-ATHEROGENIC…
  96. Apoprotein AI mimetic peptides and their potential ANTI-ATHEROGENICmechanisms of action
  97. Date (Phoenix dactylifera L.) Fruit Soluble Phenolics Composition and ANTI-ATHEROGENICProperties in Nine Israeli Varieties
  98. Enhanced CD36 expression changes the role of Nrf2 activation from ANTI-ATHEROGENICto pro-atherogenic in apoE-deficient mice
  99. The effect of intakes of fish and Camelina sativa oil on atherogenic and ANTI-ATHEROGENICfunctions of LDL and HDL particles: A randomized controlled trial
  100. The ANTI-ATHEROGENICeffects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1
  101. The endothelium as a target for ANTI-ATHEROGENICtherapy: a focus on the epigenetic enzymes EZH2 and SIRT1
  102. ANTI-ATHEROGENICeffects of CD36-targeted epigallocatechin gallate-loaded nanoparticles
  103. Ursodeoxycholic acid (UDCA) exerts ANTI-ATHEROGENICeffects by inhibiting RAGE signaling in diabetic atherosclerosis
  104. ANTI-ATHEROGENICactions of high-density lipoprotein through sphingosine 1-phosphate receptors and scavenger receptor class B type I
  105. ANTI-ATHEROGENICeffects of vaspin on human aortic smooth muscle cell/macrophage responses and hyperlipidemic mouse plaque phenotype
  106. ANTI-ATHEROGENICeffect of soya and rice-protein isolate, compared with casein, in apolipoprotein E-deficient mice
  107. Screening of ANTI-ATHEROGENICsubstances from insect resources
  108. β2-Integrin and lipid modifications indicate a non-antioxidant mechanism for the ANTI-ATHEROGENICeffect of dietary coenzyme Q10
  109. ANTI-ATHEROGENICeffects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model
  110. HDL slowing down endothelial progenitor cells senescence: a novel ANTI-ATHEROGENICproperty of HDL
  111. Functional interplay between liver X receptor and AMP‐activated protein kinase α inhibits atherosclerosis in apolipoprotein E‐deficient mice− a new anti‐atherogenic …
  112. Estrogen regulation of the scavenger receptor class B gene: ANTI-ATHEROGENICor steroidogenic, is there a priority?
  113. Physicochemical characteristics of rapidly dried onion powder and its ANTI-ATHEROGENICeffect on rats fed high-fat diet
  114. Fish and lifestyle-related disease prevention: experimental and epidemiological evidence for ANTI-ATHEROGENICpotential of taurine.
  115. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional ANTI-ATHEROGENICproperty.
  116. In vivo ANTI-ATHEROGENICproperties of cultured gilthead sea bream (Sparus aurata) polar lipid extracts in hypercholesterolaemic rabbits
  117. ANTI-ATHEROGENICproperties of vitamin E, aspirin, and their combination
  118. Hypolipidemic and ANTI-ATHEROGENICeffect of aqueous extract leaves of Ficus glumosa (Moraceae) in rats
  119. ANTI-ATHEROGENICeffects of methotrexate carried by a lipid nanoemulsion that binds to LDL receptors in cholesterol-fed rabbits
  120. Nicotinic acid has ANTI-ATHEROGENICand anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities
  121. Omega–3 fatty acids, inflammation and angiogenesis: nutrigenomic effects as an explanation for ANTI-ATHEROGENICand anti-inflammatory effects of fish and fish oils
  122. ANTI-ATHEROGENICeffects of the aqueous extract of rhubarb in rats fed an atherogenic diet
  123. Ursodeoxycholic acid (UDCA) exerts ANTI-ATHEROGENICeffects by inhibiting endoplasmic reticulum (ER) stress induced by disturbed flow
  124. ANTI-ATHEROGENICmodification of serum lipoprotein function in patients with rheumatoid arthritis after tocilizumab treatment, a pilot study
  125. Inhibition of cytokine-induced IκB kinase activation as a mechanism contributing to the ANTI-ATHEROGENICactivity of tilianin in hyperlipidemic mice
  126. Caveolin-1 regulates the ANTI-ATHEROGENICproperties of macrophages
  127. The ANTI-ATHEROGENICproperties of HDL particles
  128. Bioactive pigments of monascus purpureus attributed to antioxidant, HMG-CoA reductase inhibition and ANTI-ATHEROGENICfunctions
  129. Evaluation of in vitro antioxidant and ANTI-ATHEROGENICproperties of selected Siddha polyherbal decoctions
  130. Cell-mediated lipoprotein transport: A novel ANTI-ATHEROGENICconcept
  131. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for ANTI-ATHEROGENICserum bilirubin levels—the Framingham Heart Study
  132. ANTI-ATHEROGENICeffects of a mixture of ascorbic acid, lysine, proline, arginine, cysteine, and green tea phenolics in human aortic smooth muscle cells
  133. A novel ANTI-ATHEROGENICrole for COX-2—potential mechanism for the cardiovascular side effects of COX-2 inhibitors
  134. Anti‐atherogenic effects of high‐density lipoprotein on nitric oxide synthesis in the endothelium
  135. Mechanisms of action of the ANTI-ATHEROGENICeffect of magnesium: lessons from a mouse model.
  136. ANTI-ATHEROGENICeffects of statins: Impact on angiopoietin-2 release from endothelial cells
  137. Long term anti-diabetic, anti-hyperlipidaemic and ANTI-ATHEROGENICeffects of Carica papaya leaves in streptozotocin diabetic rats.
  138. MEK1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport—An ANTI-ATHEROGENICfunction of ERK1/2 inhibition
  139. Endothelial lipase exerts its ANTI-ATHEROGENICeffect through increased catabolism of β-VLDLs
  140. High-density lipoprotein affects antigen presentation by interfering with lipid raft: a promising ANTI-ATHEROGENICstrategy
  141. Hypolipidemic and ANTI-ATHEROGENICeffect of sulphated polysaccharides from the green alga Ulva fasciata
  142. The anti-osteoporotic and ANTI-ATHEROGENICeffects of alendronate and simvastatin in ovariectomized rats fed high fat diet: a comparative study of combination therapy …
  143. … deficiency (ASMD): Further clearance of hepatic sphingomyelin is associated with additional improvements in pro-and ANTI-ATHEROGENIClipid profiles after 42 …
  144. The hyperlipemic hamster‐a model for testing the anti‐atherogenic effect of amlodipine
  145. ANTI-ATHEROGENICproperties of allium ursinum liophylisate: Impact on lipoprotein homeostasis and cardiac biomarkers in hypercholesterolemic rabbits
  146. Treatment with PCSK9 inhibitors induces a more ANTI-ATHEROGENICHDL lipid profile in patients at high cardiovascular risk
  147. ANTI-ATHEROGENICeffects of 3, 4-dihydroxy hydrocinnamides
  148. The ANTI-ATHEROGENICproperties of sesamin are mediated via improved macrophage cholesterol efflux through PPARγ1-LXRα and MAPK signaling
  149. ANTI-ATHEROGENICproperties of resveratrol: 4-week resveratrol administration associated with serum concentrations of SIRT1, adiponectin, S100A8/A9 and …
  150. Glucocorticoid receptor-mediated upregulation of human CYP27A1, a potential ANTI-ATHEROGENICenzyme
  151. Anti‐oxidative, anti‐inflammatory and anti‐atherogenic effects of Dandelion (Taraxacum officinale) extracts in C57BL/6 mice fed atherogenic diet
  152. ANTI-ATHEROGENICeffect of trivalent chromium-loaded CPMV nanoparticles in human aortic smooth muscle cells under hyperglycemic conditions in vitro
  153. 14 Days of supplementation with blueberry extract shows ANTI-ATHEROGENICproperties and improves oxidative parameters in hypercholesterolemic rats model
  154. The ANTI-ATHEROGENICpotential of serum amyloid A peptides.
  155. Effect of N‐(p‐coumaroyl)serotonin and N‐feruloylserotonin, major anti‐atherogenic polyphenols in safflower seed, on vasodilation, proliferation and migration of …
  156. Genistein as a potential inducer of the anti‐atherogenic enzyme paraoxonase‐1: studies in cultured hepatocytes in vitro and in rat liver in vivo
  157. ANTI-ATHEROGENICeffect of BHB-TZD having inhibitory activities on cyclooxygenase and 5-lipoxygenase in hyperlipidemic mice
  158. ANTI-ATHEROGENICeffect of San-Huang-Xie-Xin-Tang, a traditional Chinese medicine, in cultured human aortic smooth muscle cells
  159. ANTI-ATHEROGENICproperties of Deglet Noor date seeds (Phoenix dactylifera) methanol extract on diet-induced hypercholesterolemic rats
  160. Sphingosine kinase inhibition exerts both pro-and ANTI-ATHEROGENICeffects in low-density lipoprotein receptor-deficient (LDL-R−/−) mice
  161. Apolipoprotein ε2 allele is associated with an ANTI-ATHEROGENIClipoprotein profile in children: the Columbia University BioMarkers Study
  162. … endothelial production of heparan sulfate rich in biologically active heparin-like domains: a potential mechanism for the ANTI-ATHEROGENICactions of vascular …
  163. Endothelium-dependent hyperpolarization as a remote ANTI-ATHEROGENICmechanism
  164. ANTI-ATHEROGENICeffects of the acyl-CoA: cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages
  165. ANTI-ATHEROGENICeffect of Humulus japonicus in apolipoprotein E-deficient mice
  166. Ginkgo biloba extract (GbE) enhances the ANTI-ATHEROGENICeffect of cilostazol by inhibiting ROS generation
  167. ANTI-ATHEROGENICantioxidants regulate the expression and function of proteasome α-type subunits in human endothelial cells
  168. Probucol and cilostazol exert a combinatorial ANTI-ATHEROGENICeffect in cholesterol-fed rabbits
  169. Alogliptin: a new dipeptidyl peptidase-4 inhibitor with potential ANTI-ATHEROGENICproperties
  170. Evaluation of nicotinic acid as an hypocholesteremic and ANTI-ATHEROGENICsubstance
  171. Cell culture as a testing system for ANTI-ATHEROGENICsubstances: a brief communication
  172. Scavenger receptor B-1 emerges as ANTI-ATHEROGENICcandidate
  173. Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces ANTI-ATHEROGENICeffects on cardiovascular risk biomarkers in HIV-infected and …
  174. Efficient coexpression and secretion of ANTI-ATHEROGENIChuman apolipoprotein AI and lecithin-cholesterol acyltransferase by cultured muscle cells using adeno …
  175. Antithrombic and ANTI-ATHEROGENICeffects of partially defatted flaxseed meal using a laser-induced thrombosis test in apolipoprotein E and low-density lipoprotein …
  176. C-terminal apolipoprotein E-derived peptide, Ep1. B, displays ANTI-ATHEROGENICactivity
  177. The ANTI-ATHEROGENICcytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1,-4 and-5 in human …
  178. Statins but not fibrates improve the atherogenic to ANTI-ATHEROGENIClipoprotein particle ratio: a randomized crossover study
  179. Evaluation of the in vitro ANTI-ATHEROGENICproperties of lipid fractions of olive pomace, olive pomace enriched fish feed and gilthead sea bream (Sparus aurata) fed …
  180. 20 (S)-protopanaxadiol saponins mainly contribute to the ANTI-ATHEROGENICeffects of Panax notoginseng in ApoE deficient mice
  181. ANTI-ATHEROGENICand anti-ischemic potentials of Croton membranaceus observed during sub-chronic toxicity studies
  182. Evaluation of the ANTI-ATHEROGENICpotential of Egyptian artichoke leaf extract in hypercholesterolemic rats
  183. ANTI-ATHEROGENICeffects of a new thienylacylhydrazone derivative, LASSBio-788, in rats fed a hypercholesterolemic diet
  184. … of a disintegrin and metalloproteinase with thrombospondin motifs 4 in human macrophages is inhibited by the ANTI-ATHEROGENICcytokine transforming growth …
  185. The ANTI-ATHEROGENICaspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory …
  186. APOA-1Milano muteins, orally delivered via genetically modified rice, show ANTI-ATHEROGENICand anti-inflammatory properties in vitro and in Apoe …
  187. Comparison of cholesterol-lowering efficacy and ANTI-ATHEROGENICproperties of hydrogenated versus non-hydrogenated (Phytrol™) tall oil-derived phytosterols in apo …
  188. ANTI-ATHEROGENICeffect of isoflavone through hypolipidemic, anti-oxidative and anti-inflammatory actions in C57BL/6 mice
  189. Androgen receptor-mediated regulation of the ANTI-ATHEROGENICenzyme CYP27A1 involves the JNK/c-jun pathway
  190. Human plasma paraoxonase (HuPON1): an ANTI-ATHEROGENICenzyme with organophosphate hydrolase activity
  191. Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated ANTI-ATHEROGENICmechanism in type II collagen induced arthritis
  192. The ANTI-ATHEROGENICeffects of lycopene
  193. The anti-hyperlipemic and ANTI-ATHEROGENICeffect of” essential” phospholipids: a pharmacologic trial
  194. Testing of ANTI-ATHEROGENICdrugs and food components on cell cultures: assessment of reliability
  195. Protamine may have ANTI-ATHEROGENICpotential by inhibiting the binding of oxidized-low density lipoprotein to LOX-1
  196. ANTI-ATHEROGENICproperties of Kgengwe (Citrullus lanatus) seed powder in low-density lipoprotein receptor knockout mice are mediated through beneficial alterations …
  197. The ANTI-ATHEROGENICeffect of dietary soybean protein concentrate in hamsters
  198. Structure and lipid interactions of an anti-inflammatory and ANTI-ATHEROGENIC10-residue class G⁎ apolipoprotein J peptide using solution NMR
  199. Multiple pathway assessment to predict ANTI-ATHEROGENICefficacy of drugs targeting macrophages in atherosclerotic plaques
  200. ANTI-ATHEROGENICproperties of emulsified perilla oil (EPO) in apo E KO mice and plasma lipid lowering effects of rice porridge containing EPO in healthy young adults
  201. ANTI-ATHEROGENICeffect of Nepitrin-7-O-glucoside: A flavonoid isolated from Nepeta hindostana via acting on PPAR–α receptor
  202. ANTI-ATHEROGENICeffects of curcumin in hypercholesterolemic rabbits
  203. Anti-thrombotic and ANTI-ATHEROGENICaction of eicosapentaenoic acid
  204. Antihypercholesterolemic and ANTI-ATHEROGENICeffects of lyophilized aqueous extract of Globularia alypum leaves in rats fed a high-cholesterol diet
  205. Inhibition of plasma lipid peroxidation by ANTI-ATHEROGENICantioxidant BO-653, 2, 3-dihydro-5-hydroxy-4, 6-di-tert-butyl-2, 2-dipentylbenzofuran
  206. Antioxidant and ANTI-ATHEROGENICProperties of Prosopis strombulifera and Tessaria absinthioides Aqueous Extracts: Modulation of NADPH Oxidase-Derived …
  207. On the ANTI-ATHEROGENICeffect of the antioxidant BHT in cholesterol-fed rabbits: inverse relation between serum triglycerides and atheromatous lesions
  208. Hypolipidemic and ANTI-ATHEROGENICActivity of Aqueous Extract of Leaves of Lagenaria siceraria in Wistar Rats
  209. ANTI-ATHEROGENICeffects of high density lipoproteins: Mechanisms
  210. Ritonavir exhibits ANTI-ATHEROGENICproperties on vascular smooth muscle cells
  211. Hypocholesterolaemic and ANTI-ATHEROGENICEffects of Palm-Based Oils (NoveLin I and NoveLin II) in Cholesterol-Fed Rabbits
  212. ANTI-ATHEROGENICeffects of resveratrol via liver X receptor α-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages
  213. ANTI-ATHEROGENICeffects of an egg yolk-enriched garlic supplement
  214. The ANTI-ATHEROGENICeffects of thiazolidinediones
  215. High density lipoproteins: the ANTI-ATHEROGENICfraction
  216. Biochemical mechanism of insulin sensitization, lipid modulation and ANTI-ATHEROGENICpotential of PPAR α/γ dual agonist: Ragaglitazar
  217. ANTI-ATHEROGENICEffects of a Phenol-Rich Fraction from Brazilian Red Wine (Vitis labrusca L.) in Hypercholesterolemic Low-Density Lipoprotein Receptor Knockout …
  218. … infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the ANTI-ATHEROGENICeffects of losartan
  219. Inhibition of LDL oxidation and inflammasome assembly by nitroaliphatic derivatives. Potential use as anti-inflammatory and ANTI-ATHEROGENICagents
  220. Significant deterioration of ANTI-ATHEROGENICefficacy of nebivolol in a double (apolipoprotein E and endothelial nitric oxide synthase) knockout mouse model of …
  221. Are calcium ion antagonists effective ANTI-ATHEROGENICagents?
  222. ANTI-ATHEROGENICaction of Panax ginseng in rats and in patients with hyperlipidemia
  223. Incretins in type 2 diabetes mellitus: cardiovascular and ANTI-ATHEROGENICeffects beyond glucose lowering
  224. The ANTI-ATHEROGENICactivity of beauveriolide derivative BVD327, a sterol O-acyltransferase 2-selective inhibitor, in apolipoprotein e knockout mice
  225. ANTI-ATHEROGENICeffects of fermented fresh coffee bean, soybean and rice bran extracts
  226. Selective peroxisome proliferator-activated receptor δ isosteric selenium agonists as potent ANTI-ATHEROGENICagents in vivo
  227. The C17-OH Group of Œstradiol: Relationships between its ANTI-ATHEROGENICand Endocrine Actions
  228. ANTI-ATHEROGENICeffects of phytosteryl oleates in apo-E deficient mice
  229. ANTI-ATHEROGENICpeptide Ep1. B derived from apolipoprotein E induces tolerogenic plasmacytoid dendritic cells
  230. Potential ANTI-ATHEROGENICcell action of the naturally occurring 4-O-methyl derivative of gallic acid on Ang II-treated macrophages
  231. The pro-inflammatory effect of uraemia overrules the ANTI-ATHEROGENICpotential of immunization with oxidized LDL in apoE−/− mice
  232. ANTI-ATHEROGENICeffects of fibrates in type 2 diabetes
  233. Folate and vitamin B12 in morbid obesity: the influence of folate on ANTI-ATHEROGENIClipid profile
  234. ANTI-ATHEROGENICproperties of fibrates may be largely due to their anti-inflammatory effects
  235. Atherogenic and ANTI-ATHEROGENICplasma lipoproteins modulate secretion of prostanoids by endothelial cells in vitro
  236. Different functional and structural characteristics between ApoA-I and ApoA-4 in lipid-free and reconstituted HDL state: ApoA-4 showed less ANTI-ATHEROGENIC…
  237. ANTI-ATHEROGENICeffects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice
  238. ANTI-ATHEROGENICRole of Peroxisome Proliferator-Activated Receptor Ligands
  239. Anti–Atherogenic Activity of Ethanol Extract of Buccholzia coriacea Seeds on Hypercholesterolemic Rats.
  240. Cholesterol-lowering and ANTI-ATHEROGENICeffects of oats in mice
  241. Lack of difference among progestins on the anti‐atherogenic effect of ethinyl estradiol: a rabbit study
  242. Gemfibrozil and its combination with metformin on pleiotropic effect on IL-10 and adiponectin and ANTI-ATHEROGENICtreatment in insulin resistant type 2 diabetes …
  243. The beneficial effects of high-density lipoprotein on adipocytes may relate to its ANTI-ATHEROGENICproperties
  244. The ANTI-ATHEROGENICmechanism of action of physical training in patients with coronary heart disease
  245. Adiponectin-a novel ANTI-ATHEROGENICfactor in the metabolic syndrome: mechanisms of action and therapeutic potential
  246. ANTI-ATHEROGENICproperties of extra virgin olive Oil
  247. Observation of Inflammatory Marker Levels in Sprague-Dawley Rats with Youngyopaedoc-san-related ANTI-ATHEROGENICEffect
  248. Inhibition of LDL oxidation and oxidized LDL-induced foam cell formation in RAW 264.7 cells show ANTI-ATHEROGENICproperties of a foliar methanol extract of …
  249. Inhibition Effect of 3-(4′-hydroxyl-3′,5′-dimethoxyphenyl)Propionic Acid in Kimchi with ANTI-ATHEROGENICActivity on the Accumulation of Lipids in the Organs of ApoE(-/-) …
  250. HO-1, a new target of PPARδ with ‘ANTI-ATHEROGENIC‘properties: is it the one?
  251. ANTI-ATHEROGENICeffect and its mechanisms of soluble egg antigen of schistosomia japonicum in ApoE-/-mice
  252. … in the binding to the protein core of biglycan of the vascular extracellular matrix: potential relationship between retention and ANTI-ATHEROGENICproperties of this …
  253. Additive ANTI-ATHEROGENICeffect of thromboxane receptor antagonism with 12/15lipoxygenase gene disruption in apolipoprotein E-deficient mice
  254. Interleukin-11: a neglected cytokine with ANTI-ATHEROGENICproperties?
  255. Mouse models of experimental atherosclerosis as a tool for checking a putative ANTI-ATHEROGENICaction of drugs
  256. Hypolipidemic and ANTI-ATHEROGENICeffects of vanadium in high-fat diet rabbits.
  257. … E knockout mice: an experimental model to study inflammatory mechanisms of atherosclerosis and to screen a putative ANTI-ATHEROGENICproperties of drugs
  258. Anti‐inflammatory and anti‐atherogenic effects of adiponectin in patients with rheumatoid arthritis following anti‐TNF therapy
  259. Characteristics of the lipid composition of atherogenic and ANTI-ATHEROGENICserum lipoproteins in patients with bronchial asthma
  260. The ANTI-ATHEROGENICrole of exercise is associated with the attenuation of bone marrow-derived macrophage activation and migration in hypercholesterolemic …
  261. Sardine purified proteins improve blood pressure, glycemic control, ANTI-ATHEROGENICmetabolic pathways and antioxidant capacity in obese rats
  262. Does ANTI-ATHEROGENICestradiol valerate treatment cause adverse effects on liver and uterus in NZW rabbits?
  263. Cross-talk between exogenous statins and endogenous high-density lipoprotein in anti-inflammatory and ANTI-ATHEROGENICactions
  264. The ANTI-ATHEROGENICActivity of Artemisia, Thyme & Soya bean
  265. P58 Potential ANTI-ATHEROGENICeffects of hydrogen-sulfide releasing molecules
  266. ANTI-ATHEROGENICeffect of Ca2+-antagonists
  267. Ezetimibe–new anti‐atherogenic properties?
  268. Pre-clinical evaluation of the hypotensive and ANTI ATHEROGENICactivity of hydroethanolic extract of Eribroma oblongum (Malvaceae) stem bark on wistar rats models
  269. The Effects of ANTI-ATHEROGENICProperties of Beverage of the Date Seeds (Phoenix Dactilifera L.) In Pre-Menopause Women: A Study Of Indonesian Women
  270. ANTI-ATHEROGENICAction of “Cardipro”-A Herbal Proprietary Formulation
  271. … (NMN) supplementation promotes anti-aging miRNA expression profile in the aorta of aged mice, predicting epigenetic rejuvenation and ANTI-ATHEROGENICeffects.
  272. Lactobacillus fermentum ME-3–a probiotic with potential for ANTI-ATHEROGENIC, anti-oxidative and anti-diabetic application
  273. Demonstration of an add-on effect of probucol and cilostazol on the statin-induced ANTI-ATHEROGENICeffects
  274. The adenosine A2A receptor agonist UK-432,097 stimulates expression of ANTI-ATHEROGENICreverse cholesterol transport proteins
  275. Metabolic and ANTI-ATHEROGENICeffects of long-term benfluorex in dyslipidemic insulin-resistant sand rats (Psammomys obesus)
  276. ANTI-ATHEROGENICeffects of supplementation with vitamin B6 (Pyridoxine) in albino rats
  277. The ANTI-ATHEROGENICeffects of eicosapentaenoic and docosahexaenoic acid are dependent on the stage of THP-1 macrophage differentiation
  278. ANTI-ATHEROGENICproperties of high-density lipoproteins in psychiatric patients before and after two months of atypical anti-psychotic therapy
  279. ANTI-ATHEROGENICactivity of wild grape (Vitis thunbergii) extract antagonizing smooth muscle cell proliferation and migration promoted by neighboring macrophages
  280. The role of 15-lipoxygenase in atherogenesis. Pro-and/or ANTI-ATHEROGENICaction
  281. ANTI-ATHEROGENICdrugs
  282. Comparative ANTI-ATHEROGENICEffects of a Single Intravenous Injection of rAAV8 Or rAAV2 Encoding Apo A-IMilano Gene
  283. Anti-inflammatory and ANTI-ATHEROGENICrole of BMP receptor II in atherosclerosis
  284. ANTI-ATHEROGENICeffect of green tea product through hypolipidemic and anti-oxidative action in ovariectomized rats
  285. Immunomodulatory activity of ANTI-ATHEROGENICdrugs: effects on blastogenesis, humoral response, delayed hypersensitivity and passive anaphylaxis by immune …
  286. How to use ezetimibe as an ANTI-ATHEROGENICagent via inhibition of rho-Kinase
  287. Bone marrow angiotensin AT2 receptor deficiency aggravates atherosclerosis development by eliminating macrophage liver X receptor-mediated ANTI-ATHEROGENIC…
  288. Multi-functional aspects of high density lipoprotein as an ANTI-ATHEROGENIClipoprotein in vivo: evidence from in vitro experiments using macrophages
  289. ANTI-ATHEROGENICeffects of cryopreserved preparation of fetoplacental complex in experimental atherosclerosis
  290. Re-Programming Atherosclerotic Plaque Macrophages Towards An ANTI-ATHEROGENICPhenotype
  291. P5330 Evaluating lipid-lowering and ANTI-ATHEROGENICeffect of injectable Curcumin in a rabbit model of atherosclerosis
  292. Mechanisms of ANTI-ATHEROGENICaction of probucol
  293. Concurrent training promoted sustained ANTI-ATHEROGENICbenefits in the fasting plasma triacylglycerolemia of postmenopausal women at 1-year follow-up
  294. Possible ANTI-ATHEROGENICeffects of emodin, an anthraquinone from Chinese herbs and Aspergillus and Penicillium fungi.
  295. Approaches for the Design of Novel ANTI-ATHEROGENICCompounds
  296. Anti‐Atherogenic Effects of Lesion‐Targeted Epigallocatechin Gallate (EGCG)‐Loaded Nanoparticles
  297. Antioxidant and ANTI-ATHEROGENICProperties of Hawthorn Vinegar in Drosophila melanogaster Fed a High-Fat Diet.
  298. Methotrexate improves pro-and ANTI-ATHEROGENICgenomic expression in psoriatic skin
  299. Anti‐Atherogenic Potential of Edible Mushrooms
  300. Comparative study of hydrochlorothiazide and indapamide on the ANTI-ATHEROGENICpotential of losartan in cholesterol fed rat
  301. ANTI-ATHEROGENICEffect of Green Tea
  302. ANTI-ATHEROGENICFUNCTIONS OF HIGH DENSITY LIPOPROTEINS
  303. Effect of Aqueous Seed Extract of Carica Papaya on Lipid Profile and Anti‐Atherogenic Index of Wistar Rat Following Cholesterol Administration
  304. Evaluation of ANTI-ATHEROGENICproperties of ezetimibe using 3H-labeled LDL and 99mTc-cAbVCAM1-5 SPECT imaging in ApoE-/-mice fed a paigen diet
  305. Lecithin cholesterol acyltransferase: an anti-or pro-atherogenic factor?
  306. Anti-inflammatory peptides grab on to the whiskers of atherogenic oxidized lipids
  307. Antioxidant and cholesterol lowering properties of 2, 6-di-t-butyl-4-[(dimethylphenylsilyl) methyloxy] phenol and derivatives: a new class of ANTI-ATHEROGENIC…
  308. Cholesteryl Ester Transfer Protein Genotype Predicts ANTI-ATHEROGENICLipid Profile and Decreased Risk of Ishemic Heart Disease, Ischemic Cerebrovascular Disease …
  309. eNOS-NO system contributes to a novel ANTI-ATHEROGENICeffect of Leonurine via inflammation inhibition and plaque stabilization
  310. Effect of an ANTI-ATHEROGENICdiet, including soy protein products with various levels of phytoestrogens, on indicators of humoral immunity in patients with hypertension …
  311. Intervention with anti-inflammatory RVE1 attenuates atherosclerosis without decreasing plasma cholesterol and adds to the ANTI-ATHEROGENICeffect of atorvastatin
  312. ANTI-ATHEROGENICeffect of NIP-200 on the experimental atherosclerosis in cholesterol-fed rabbits
  313. ANTI-ATHEROGENICactions of (+)-catechin
  314. 0383: anti-inflammatory and ANTI-ATHEROGENICeffects of the inflammasome NLRP3 inhibitor, arglabin, in ApoE2Ki mice fed a high fat diet
  315. Chemical Composition, Anti-neuraminidase, and ANTI-ATHEROGENICActivities of the Essential Oil from two Varieties of Alpinia zerumbet Leaves
  316. Endothelial lipase exerts its ANTI-ATHEROGENICeffect through increased catabolism of β-VLDLS
  317. Insulin-like growth factor-1 upregulates junction proteins in vascular endothelial cells: potential mechanisms for ANTI-ATHEROGENICeffect of insulin-like growth factor-1
  318. ANTI-ATHEROGENICEffect of Oleanolic Acid Appears Unrelated to Endothelial Release of Nitric Oxide
  319. A new anti‐atherogenic strategy
  320. ANTI-ATHEROGENICactions of dihomo-gamma-linolenic acid in macrophages
  321. Pioglitazone treatment may lead to ANTI-ATHEROGENICalterations of lipoproteins through increasing serum adiponectin in statin-treated diabetes patients
  322. ANTI-ATHEROGENICAction of Eicosapentaenoic Acid
  323. Loss of macrophage LDL receptor related protein 1 (LRP1) confers resistance to the ANTI-ATHEROGENICeffects of TNFα inhibition
  324. ANTI-ATHEROGENICDiets: Observations from Mouse Models
  325. Adoptive Cell Transfer Demonstrates that CD8+ T cells Mediate the ANTI-ATHEROGENICEffects of the ApoB-100 Peptide P210 Immunization in ApoE−/− Mice
  326. ADENOVIRAL EXPRESSION OF HUMAN LCAT IN NON-HUMAN PRIMATES LEADS TO AN ANTI-ATHEROGENICLIPOPROTEIN PHENOTYPE BY …
  327. Disturbed Flow-Targeting Nanovesicles for ANTI-ATHEROGENICTheragnosis
  328. ANTI-ATHEROGENICeffects of resveratrol via liver X receptor a-dependent upregulation of ATP-binding cassette transporters A1 and G1 in macrophages
  329. Anti-inflammatory and ANTI-ATHEROGENICEffects of Lactobacillus plantarum in Hypercholesterolemic Mice
  330. ANTI-ATHEROGENICactions of dihomo-gamma-linolenic acid and its key metabolites
  331. Sphingosine 1-phosphate (S1P) receptor type 1 signaling induces an ANTI-ATHEROGENICphenotype in macrophages and attenuates atherosclerosis in LDL-receptor …
  332. Involvement of Vascular Endothelial Cells in the ANTI-ATHEROGENICEffects of Liraglutide in Diabetic Apolipoprotein E-null Mice
  333. Anti-inflammatory, antioxidative and ANTI-ATHEROGENICbioactivity in marine sources ascribed to nonlipid constituents
  334. The role of the ERK1: STAT1 serine 727 phosphorylation axis on key atherosclerosis associated cellular processes and the ANTI-ATHEROGENICactions of hydroxytyrosol
  335. Fish and camelina sativa oil: effects on fatty acid composition of blood lipid fractions, lipoprotein subclasses and pro-and ANTI-ATHEROGENIClipoprotein functions
  336. Antihypercholesterolemic, antioxidative and anti-inflammatory potential of an extract of the plant Tabernaemontana divaricata in experimental rats fed an atherogenic …
  337. ANTI ATHEROGENICEffects of Micro RNA-21
  338. Ateronon: First clinically proven ANTI-ATHEROGENICantioxidant
  339. Atherogenic and ANTI-ATHEROGENICrisk markers in subjects with obesity and/or type 2 diabetes
  340. ANTI-ATHEROGENICEffect of Nuts: Is the Answer NO?-Reply
  341. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents
  342. THE ANTI-INFLAMMATORY AND POTENTIAL ANTI-ATHEROGENICEFFECT OF INSULIN
  343. Vascular endothelial expression of atherogenic and ANTI-ATHEROGENICproteins in humans: Relations to cardiovascular disease risk factors
  344. Anti-inflammatory and ANTI-ATHEROGENICrole of IL-32α in vascular endothelium
  345. Plasma level of atherogenic and ANTI-ATHEROGENICfactors among palm wine drinkers of rural Southwest Nigeria
  346. Application of the cDNA array system for screening ANTI-ATHEROGENICagents
  347. Testing of anti‐atherogenic drugs on cell cultures: reliability questioned
  348. Evaluation of ANTI-ATHEROGENICeffects of P2Y12 receptor antagonists in Apolipoprotein E-deficient mice
  349. In vivo antioxidant action and ANTI-ATHEROGENICeffect of a novel antioxidant (BO-653)
  350. ANTI-ATHEROGENICproperties of HDL: Insights from the AIMilano mutation
  351. IgM autoantibodies against lipoprotein (A) as an “ANTI-ATHEROGENIC” factor in patients with severe hyperlipidemia
  352. Abstract# 2703: Anti-carcinogenic and ANTI-ATHEROGENICpotential of dietary phytochemicals
  353. ANTI-ATHEROGENICProperties of Heme Oxygenase
  354. Anti‐atherogenic Effect of T0901317 Nanovesicles in THP‐1 Derived Macrophages
  355. Mountain tea (Sideritis plants): A potential ANTI-ATHEROGENICagent?
  356. Erratum to: Cell Culture as a Testing System for ANTI-ATHEROGENICSubstances: A Brief Communication
  357. PROGNOSTIC IMPLICATIONS OF ATHEROGENIC/ANTI-ATHEROGENICLIPID RATIOS IN AN ETHNICALLY DIVERSE POPULATION.
  358. OP22 The impact of estrogen on the ANTI-ATHEROGENICeffect of H2S
  359. MECHANISMS OF ACTION OF PHENOLIC COMPOUNDS FOCUSES ON THEIR ANTI-OXIDATIVE AND ANTI-ATHEROGENICEFFECTS
  360. ANTI-ATHEROGENICEffects of Cureumin in Hypercholesterolemic Rabbits
  361. ANTI-ATHEROGENICeffects of dietary supplementation of Kgengwe (Citrullus lanatus) seed powder in low density lipoprotein receptor knock-out mice
  362. Identification of ANTI-ATHEROGENICand Anti-inflammatory Effects of Walnuts and Pistachios
  363. Effect of heating on the ANTI-ATHEROGENICaction of sunflower oil.
  364. Anti-inflammatory and ANTI-ATHEROGENICeffects of 9E,11E-conjugated linoleic acid
  365. Rosemary as ANTI-ATHEROGENICfood ingredient
  366. ANTI-ATHEROGENICmechanisms of berberine
  367. Long term hypolipidaemic and ANTI-ATHEROGENICeffects ofCarica papaya Linn. administration on normal rabbits
  368. Anti‐atherogenic effect of blue‐green algae in male apolipoprotein E knockout mice fed an atherogenic diet
  369. Novel ANTI-ATHEROGENICeffects of MH13 in vascular smooth muscle cells
  370. Study on Effects of Food Factors and ANTI-ATHEROGENICLipoprotein Function (Young Investigator Award of JSFNS (2013))
  371. Lipoprotein interactions with the arterial wall: Pro-vs. ANTI-ATHEROGENICeffects
  372. Therapeutic strategies in management of atherosclerosis by manipulation of ANTI-ATHEROGENICB1a lymphocytes
  373. ANTI-ATHEROGENICeffect of circylating immune complexes in schistosomal hepatic fibrosis
  374. Anti‐atherogenic effect of dandelion extracts through anti‐inflammatory and anti‐oxidative processes in C57BL/6 mice
  375. ANTI-ATHEROGENICpotential of γ-linolenic acid.
  376. ANTI-ATHEROGENICeffect of calcium antagonist plus statin cotreatment realises at lipoprotein level
  377. ANTI-ATHEROGENICeffects of liraglutide in hyperglycemic apolipoprotein E-null mice via AMP-activated protein kinase 2 independent mechanisms 3
  378. Different association of serum docosahexaenoic acid and eicosapentaenoic acid levels with atherogenic and ANTI-ATHEROGENIClipoproteins in statin-treated diabetes …
  379. Physicochemical characteristics of rapidly dried onion powder and its ANTI-ATHEROGENICeffect
  380. A Study of Antiobesity, Hypolipidemic and ANTI-ATHEROGENICActivity of Poly Herbal Formulation against High Fat Diet-Induced Obesity in Albino Rats
  381. ANTI-ATHEROGENICEffects of the Methanol Extract of Sorbus Cortex in Atherogenic-Diet Rats (Pharmacognosy)
  382. Comparison of the ANTI-ATHEROGENICand Anti-metabolic Effects Between Miglitol and Nteglinide in Diabetic Patients with Coronary Artery Disease
  383. Thromboxane receptor blockade improves the ANTI-ATHEROGENICeffect of
  384. ANTI-ATHEROGENIC, Anti-Inflammatory, and Anti-Hypertensive Effects of Peanuts Determined with In Vivo and In Vitro Models
  385. ANTI-ATHEROGENICeffect of enterosorption in patients with diabetes mellitus
  386. The ANTI-ATHEROGENICActivity of Luteolin and Luteolin-7-O-glucoside in High-Fat Diet-Administered Hyperhomocysteinemia-Induced C57BL/6J Mice
  387. Novel pro-and ANTI-ATHEROGENICeffects of apolipoprotein B-containing lipoproteins: To feast or to fast?
  388. ANTI-ATHEROGENICeffect of circulating immune complexes in schistosomal hepatic fibrosis
  389. Fish oil supplementation induces ANTI-ATHEROGENICgene expression profiles in human blood mononuclear cells
  390. Anti-Inflammatory and ANTI-ATHEROGENICActivities of Ncx 6560, a Nitric Oxide (no)-Donating Statin, in Hypercholesterolemic Mice
  391. ANTI-ATHEROGENICEffects of Functional Sujeonggwa Drinks in Hypercholesterolemic Apo E KO Mice
  392. ANTI-ATHEROGENICAND ANTI-ANGIOGENIC EFFECTS OF DONEPEZIL, A DRUG FOR ALZHEIMER’S DISEASE
  393. Analysis of the Molecular Organization of Lipoprotein-Associated Apolipoprotein E, an ANTI-ATHEROGENICProtein
  394. CYP1A1 and CYP1B1 expression and free zinc levels in endothelial cells are differentially regulated by pro-atherogenic versus ANTI-ATHEROGENICshear stress
  395. Studies on the Pathogenesis of Atherosclerosis and Development of ANTI-ATHEROGENICSmall Molecule Using Gene Targeted Mouse
  396. Hypolipidemic and anti‐atherogenic effect of omega‐3 enriched structured lipids from linseed oil (LSO) with refined palm olein oil (RPOO) on rats fed atherogenic diet
  397. Platycodin D lowers cholesterol in vivo and has ANTI-ATHEROGENICproperties in vitro
  398. Apolipoprotein B Bound To Erythrocytes: A Novel ANTI-ATHEROGENICLipid Transport Pathway
  399. < The> metabolic effect of partial lipectomy in old aged rats and the associated changes in the ANTI-ATHEROGENICindex: adiponectin/leptin ratio
  400. ANTI-ATHEROGENICfunction of LPL in human and porcine coronary endothelial cells
  401. Comparison the ANTI-ATHEROGENICand hypolipidaemic effect of Cod liver oil, pomegranate seed oil and Rosuvastatin in hyperecholestrolemic rats
  402. Pro-and ANTI-ATHEROGENICeffects of a dominant negative P465L mutation of PPARγ in apolipoprotein E-null mice
  403. ANTI-ATHEROGENICEffect of Novel Peroxisome Proliferator-Activated Receptor δ Agonist RSC-451061 Hydrochloride Accompanied by Anti-Inflammatory Effects in LDL …
  404. Statin treatment potentiates the lipid-lowering and ANTI-ATHEROGENICeffect of bat activation by accelerating lipoprotein remnant clearance
  405. HDL and ABC Transporters Reduce the Proliferation of Hematopoietic Stem and Progenitor Cells, with ANTI-ATHEROGENICConsequences
  406. ANTI-ATHEROGENICproperties of paraoxonase 2 and paraoxonase 3: In vitro and in vivo studies
  407. Kruppel-like factors: emerging regulators mediating the ANTI-ATHEROGENICeffects of flow shear stress
  408. FENOFIBRATE-MEDIATED ANTI-ATHEROGENICACTIVITY: LONG-TERM FOLLOW-UP STUDY OF RHEUMATOID ARTHRITIS PATIENTS BY COMPARING …
  409. 11: THE ADENOSINE A2A RECEPTOR AGONIST UK-432,097 STIMULATES ANTI-ATHEROGENICREVERSE CHOLESTEROL TRANSPORT PROTEINS IN THP-1 …
  410. The Role of Scavenger Receptor-A in Heat Shock Protein 27-mediated Atheroprotection: Mechanistic Insights into a Novel ANTI-ATHEROGENICTherapy
  411. Novel anti‐atherogenic effects of trivalent chromium in vascular smooth muscle cells: therapeutic implication for diabetic vascular complications
  412. Schistosoma Mansoni infection induces ANTI-ATHEROGENICtranscriptional changes in hepatic macrophages (MPF2P. 758)
  413. Nanoencapsulation Enhances Epigallocatechin Gallate (EGCG) Stability and Its ANTI-ATHEROGENICBioactivities in Macrophages
  414. 66-mercaptopurine induces ANTI-ATHEROGENICeffects in monocytes/macrophages and inhibits
  415. eNOS-NO system attributes to novel ANTI-ATHEROGENICeffect of leonurine via inflammation inhibition and plaque stabilization
  416. ANTI-ATHEROGENICand Nephroprotective Effects of Tocotrienol Rich Fraction (TRF) from Palm Oil and Rice Bran Oil
  417. ANTI-ATHEROGENICeffects of long term benfluorex treatment in insulino-resistant Sand rats (Psammomys obesus)
  418. ANTI-ATHEROGENICEffects of Hexane Extracts of Yam, Dioscorea batatas Decne
  419. In vitro radical scavenging activity of short arm octopus added kimchi and its ANTI-ATHEROGENICeffects in Apo E KO mice
  420. ANTI-ATHEROGENICAND ANTIOXIDANT POTENCY OF TINOSPORA CRISPA IN RABBITS FED WITH HIGH FAT DIET.
  421. Change of natural antibody levels in patients with cardiovascular diseases by the use of ANTI-ATHEROGENICdiets with processed soy product foods
  422. Inhibition of Cytokine Induced I-B Kinase Activation as a Mechanism Contributing to the ANTI-ATHEROGENICActivity of Tilianin in Hyperlipidemic Mice
  423. The effect of antibodies against high-density lipoprotein (aHDL) and apolipoprotein AI (aApo AI) on the ANTI-ATHEROGENICand anti-inflammatory properties of HDL in …
  424. Niacin improves ANTI-ATHEROGENICeffect of statins in APOE* 3Leiden. CETP mice
  425. Functional interplay between LXR and AMPK inhibits atherosclerosis in apoE deficient mice——A new ANTI-ATHEROGENICstrategy
  426. Assessment of ANTI-ATHEROGENICdrugs in vivo and reconstitution of lipoproteins using radioiodinated cholesteryl iopanoate
  427. Beyond LDL Cholesterol: Carriers of the PCSK9 R46L Variant Are Characterized by an ANTI-ATHEROGENICLipoprotein Profile Assessed by Nuclear Magnetic …
  428. Viral ANTI-ATHEROGENICProteins Alter Monocyte and Neutrophil Invasion in Mice and Bag3 Gene Expression
  429. Bone Marrow Angiotensin AT2 Receptor Deficiency Aggravates Atherosclerosis by Eliminating Macrophage Liver X Receptor-Mediated ANTI-ATHEROGENICActions
  430. Opuntiol and opuntioside-I an ANTI-ATHEROGENICagent interfering with chemotaxis via IPLA2B-dependent F-actin polymerization in human monocyte
  431. Molecular Pathology: Poster# 247 OPUNTIOL AND OPUNTIOSIDE-I AN ANTI-ATHEROGENICAGENT INTERFERING WITH CHEMOTAXIS VIA IPLA2B-DEPENDENT …
  432. English walnut (Juglans regia) and human immune function: Support of the ANTI-ATHEROGENICproperties of walnuts and identification of a new link in …
  433. Combination Therapy with Olmesartan and Azelnidipine Exerts ANTI-ATHEROGENICEffects in Diabetic Apolipoprotein E-Deficient Mice
  434. VIRAL ANTI-ATHEROGENICPROTEINS ALTER MONOCYTE AND NEUTROPHIL INVASION IN MICE WITH ALTERED BAG3 GENE EXPRESSION
  435. Resveratrol Protects against Atherosclerosis, but Does not Add to the ANTI-ATHEROGENICEffect of Atorvastatin, in APOE* 3-Leiden. CETP Mice
  436. Cilostazol Selectively Increases ANTI-ATHEROGENICHDL Subclass (LpA-I particles) in Male Patients with Non-insulin Dependent Diabetes Mellitus
  437. … of Differentially Expressed Genes in the Aortae of Apoe-deficient Mice Infused with Insulin-like Growth Factor I: Novel Mechanisms of the ANTI-ATHEROGENICEffect of IGF …
  438. Supplementary Material to Conditional linkage and genome-wide association studies identify UGT1A1 as major gene for ANTI-ATHEROGENICserum bilirubin levels–a …
  439. ANTI-ATHEROGENICproperties associated with the antioxidant activity from the hydrophilic extracts of Halimeda incrassata (Chlorophyta, Bryopsidales)
  440. The anti‐atherogenic potential of C‐type natriuretic peptide: Disparate regulation of endothelial and vascular smooth muscle cell proliferation via natriuretic peptide …
  441. Apolipoprotein J (clusterin) induces cholesterol export from macrophage foam cells: A potential ANTI-ATHEROGENICfunction?
  442. … T Lymphocytes Recruitment by Inhibiting T Lymphocytotropic CXC Chemokines in LPS-Stimulated Macrophages: A Potential ANTI-ATHEROGENICFunction of Adiponectin
  443. Attenuated ANTI-ATHEROGENICEffects by Statins in Diabetic Patients in Comparison with Non-diabetic Patients; Non-invasive Quantitative Analysis of Coronary …
  444. Is the Post-menopausal Rise in PCSK9 Levels Due to Loss of the Estrogen Responsive ANTI-ATHEROGENICProtein, Heat Shock Protein 27? Insights Into a Potential New …
  445. Circulating Markers Reflect Both Anti-and Pro-Atherogenic Drug Effects in ApoE-Deficient Mice
  446. Immunomodulatory and anti-angiogenic properties of Linum usitatissium (flaxseed) seeds ethanolic extract in atherogenic diet treated rats
  447. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
  448. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE* 3Leiden. CETP mice
  449. ApolipoproteinA1-75 G/A (M1-) polymorphism and lipoprotein (a); anti-vs. pro-atherogenic properties
  450. Anti-obesity potential of almond (Prunus dulcis) in experimental animals under cafeteria and atherogenic diets
  451. Malvidin 3-glucoside, a dietary anthocyanin, contributes to the balance between pro-and anti-inflammatory mediators in human endothelial cells: a potential role …
Related Posts

Cyp2e1

BCL-2

Pyrazines

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping